The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)

NCT ID: NCT04564937

Last Updated: 2020-09-25

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 66 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-06
• Study Completion Date: 2022-10-31

Brief Summary

Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody（SCT510A）

Conditions

Wet Age-related Macular Degeneration

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SCT510A dose level 1 treatment

SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously

Group Type: EXPERIMENTAL

SCT510A

Intervention Type: DRUG

SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

SCT510A dose level 2 treatment

SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously

Group Type: EXPERIMENTAL

SCT510A

Intervention Type: DRUG

SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

SCT510A dose level 3 treatment

SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously

Group Type: EXPERIMENTAL

SCT510A

Intervention Type: DRUG

SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

SCT510A dose level 4 treatment

SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously

Group Type: EXPERIMENTAL

SCT510A

Intervention Type: DRUG

SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

Interventions

SCT510A

SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent form;

2. Age≥45 years，≤80 years，male or femal;

3. The study eye must meet the following criteria： Diagnosis of wAMD； Primary or recurrent active subfoveal or parafoveal choroidal neovascularization (CNV) lesions secondary to AMD； Total area of all types of lesions ≤12 optic disc areas（30mm2）； Best-corrected visual acuity of the study eye 70 letters or worse(Snellen equivalent of 20/40 or worse)； No optometric media opacity and pupil shrinkage.

4. Best-corrected visual acuity of the fellow eye 19 letters or better（Snellen equivalent of 20/400 or better）.

Exclusion Criteria

1. The study eye suffers structural damage of retinal which involves fovea，and the investigator assess that there is a risk of retinal detachment；

2. Significant afferent pupillary defect (APD) in the study eye；

3. The study eye has no lens( except intraocular lens) or posterior capsular rupture of the lens；

4. In addition to AMD，there are other obvious eye diseases/conditions，such as pseudoexfoliation syndrome，rhegmatogenous retinal detachment，macular hole，diabetic retinopathy and diabetic macular disease which need to be treated；

5. CNV caused by other causes other than wAMD, such as vascular stripe disease, ocular histoplasmosis, case myopia, trauma, etc；

6. Uncontrolled glaucoma in the study eye (defined as IOP≥25mmHg after antiglaucoma treatment),or recevied glaucoma filtering surgery；

7. History of vitreous hemorrhage in the study eye within 2 months before the first administration；

8. Active inflammation or infection in either eye, such as conjunctivitis,keratitis, scleritis, endophthalmitis, or uveitis，ect；

9. Previous intraocular surgery ，or laser therapy for wAMD(as photodynamic therapy,transpupillary thermotherapy,etc.) in the study eye within 3 months before the first administration；

10. Previous intraocular or periocular injection of anti-VEGF or corticosteroid drugs (such as ranibizumab, bevacizumab, conbercept, aflibercept, brolucizumab, pegaptanib sodium, anecortave acetate, triamcinolone acetonide, etc.) in either eye within 3 months before the first administration；

11. History of allergy to fluorescein sodium or indocyanine green；

12. PLT≤100×109/L；thrombin time and prothrombin time exceed the upper limit of normal range (based on the laboratory normal value of clinical trial institution), and the abnormality is clinically significant according to the evaluation of the investigators；

13. Abnormal liver and kidney function；

14. Uncontrolled blood pressure control，systolic blood pressure≥160mmhg ,or diastolic blood pressure≥100mmhg；

15. History of surgery within one month before the first administration, or current non-healing wound, ulcer, or fracture，etc；

16. Patients with any of the following serious systemic diseases，such as serious mental, neurological, cardiovascular, respiratory and other system diseases and malignant tumors, systemic immune system diseases, diabetes mellitus with uncontrolled blood sugar(HbA1c>10%), disseminated intravascular coagulation and significant bleeding tendency；

17. Suffering from systemic infectious diseases requiring oral, intramuscular or intravenous administration；

18. Pregnant, lactating women and the patients who can not take contraceptive measures.

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sinocelltech Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Ming Guo

Role: CONTACT

ming_guo@sinocelltech.com

+86-10-58628288-9138

Other Identifiers

SCT510A-A101

Identifier Type: -

Identifier Source: org_study_id